Check out our most popular compounded medications! Get Started
Licensed to fill prescriptions for patients in RI, MA, CT, NJ, NH, FL, ME and PA. New York patients are served on a limited basis while nonresident registration is pending.
Prepared to a prescriber's order for one patient. Not FDA-approved.
This is a compounded slow release capsule containing liothyronine sodium, prepared to a prescriber's order for one patient. Compounded preparations are not FDA-approved.
These listings cover every salt or ester form of each drug in the FDA National Drug Code Directory.
FDA-approved products containing liothyronine are listed in tablet and injection forms. No finished liothyronine product of any kind is listed in capsule form.
This is a solid, nonaqueous dose form. Under USP <795>, nonaqueous preparations carry longer default beyond-use dates than water-containing ones. The date printed on the label is the one to follow.
Liothyronine (T3) is a synthetic thyroid hormone that compounding pharmacies prepare as oral capsules, including slow-release forms, in strengths not manufactured, by prescription.
Liothyronine is the synthetic form of triiodothyronine (T3), the more active of the two thyroid hormones. In the body most T3 comes from conversion of thyroxine (T4) in peripheral tissues; T3 enters the cell nucleus, binds thyroid hormone receptors and switches on gene transcription that sets metabolic rate, heart rate and growth. The manufactured products are Cytomel (liothyronine sodium tablets, Pfizer) and generics, FDA-approved for replacement therapy in primary, secondary and tertiary hypothyroidism, as an adjunct to surgery and radioiodine for TSH suppression in well-differentiated thyroid cancer, and as a diagnostic agent in thyroid suppression tests; an injection also exists. The tablets come in a few fixed strengths and release the whole dose at once, so a prescriber might order compounded liothyronine in a fractional strength, as a slow-release capsule, or free of a specific excipient. Compounded preparations are not FDA-approved and require a prescription.
Liothyronine carries the FDA boxed warning shared by all thyroid hormones: it must not be used for obesity or weight loss, because doses beyond the body's hormonal requirement can cause serious or life-threatening toxicity, especially with sympathomimetic amines such as amphetamines. Do not use it with uncorrected adrenal insufficiency, which must be treated first. Too much thyroid hormone strains the heart, causing palpitations, fast or irregular heartbeat, angina and, in older adults or people with heart disease, heart attack; over-replacement also thins bone and can worsen diabetes control. It increases the effect of warfarin and reduces the effect of digoxin. Bile acid binders such as cholestyramine block its absorption and should be taken at least four hours apart; estrogens, androgens, phenytoin, carbamazepine, rifampin, amiodarone, high-dose propranolol, antidepressants and ketamine can change its levels or effects. Requirements rise in pregnancy and treatment should not be stopped; the label says liothyronine is present in milk with too little information on infant effects, and Drugs.com's breastfeeding monograph, citing primary studies, notes T3 is a normal milk component. Signs of excess are weight loss, nervousness, sweating, heat intolerance, tremor, insomnia and hair loss. Call your prescriber for chest pain or a racing or irregular pulse. If side effects bother you, talk to your prescriber or pharmacist.
Liothyronine is synthetic T3; thyroid hormones act through nuclear receptor binding and regulation of DNA transcription and protein synthesis. About 95 percent of an oral dose is absorbed within 4 hours; T3 is less firmly protein bound than T4, which explains its lower serum levels and shorter half-life of about 2.5 days; onset is within hours with maximal response in 2 to 3 days. Immediate-release dosing produces a sharp serum T3 peak at about 2 to 4 hours that can exceed the reference range and perturb TSH, unlike the flat physiologic profile (Dayan and Panicker, Thyroid Research 2018). Labeled indications (Cytomel): hypothyroidism, TSH suppression in well-differentiated thyroid cancer, thyroid suppression testing; not indicated for myxedema coma. Prescribers have ordered compounded liothyronine, including slow-release capsules, for patients with persistent symptoms on levothyroxine alone as part of a supervised T4 plus T3 trial; the 2018 review reports that meta-analyses of randomized trials found no population-level benefit of combination therapy, that the ATA does not recommend compounded T3 except for documented allergy to commercial products and cites thyrotoxicosis and hypothyroidism from compounding errors, and that no commercial sustained-release T3 exists. Dosing, strength and titration are per prescriber, starting low in the elderly and in cardiovascular disease. Monitor TSH after initiation and dose change and every 6 to 12 months once stable, total T3 where TSH is unreliable, growth in children, INR with anticoagulants, and bone density in postmenopausal women. Not a controlled substance.
Swallow the capsule whole with fluid. Do not crush, chew, divide or open it, and do not dissolve it in liquid, because that can release the full dose at once. Take it at the same times each day as your label directs. Slow release forms are not meant for feeding tubes; ask your pharmacist if you need a different form.
These are nonaqueous capsules, so a USP <795> default beyond-use date of up to 180 days usually applies. Store in a closed container at room temperature, away from heat, moisture and direct light, and out of reach of children. Discard after the beyond-use date on the label.
This formulation is compounded by Bayview Pharmacy on a prescriber's order for an individual patient. It is not an FDA-approved drug product, and the FDA has not evaluated it for safety, effectiveness, or manufacturing quality.
A valid prescription is required. Availability depends on Bayview's licensure in your state. This page is general information, not medical advice. Discuss your situation with a licensed healthcare provider.
Search by NCPDP 4106882, or by name and ZIP: Bayview Pharmacy, Warwick, RI 02886. Select it as the destination pharmacy and save it as a favorite. Click any value to copy it.
Compounded preparations have no NDC, so this formula will not appear in your EHR's drug search. Use your system's compound, non-formulary, or free-text prescription entry and name the preparation exactly as written in step 3. If your EHR forces you to pick a listed drug, pick the closest entry for the active ingredient and put the full formula in the prescription body (the Sig or directions field), not in Notes to Pharmacy.
Compounded preparations have no NDC and will not appear in your drug search. For EPCS to validate, select a drug entry your EHR recognizes as controlled, usually the bulk powder entry for the active ingredient (for example Ketamine (bulk) powder, not a branded product), then put the full formula from step 3 in the prescription body. A free-text entry that does not validate as controlled will be rejected by your EPCS module.
Quantity and directions are starting points for this dose form, not treatment recommendations. Dosing remains the prescriber's responsibility.
Transmit from your EHR. For this non-controlled preparation we also accept fax to (401) 284-4506 and phoned orders at (401) 284-4505. Order forms are on the formulation pages and in the prescriber portal.
Transmit with two-factor authentication through your EPCS-enabled EHR. No order form is offered for this preparation; e-prescribing guides for our controlled preparations are on the formulation pages.
Licensed to dispense in RI, MA, CT, NJ, NH, FL, ME, and PA; New York is served on a limited basis while nonresident registration is pending. Compounded preparations are not FDA-approved. A valid prescription is required. Full guide, including steps by EHR: How to e-prescribe to Bayview. Questions about this formula: call (401) 284-4505.
Take 1 capsule by mouth
